GEMINI THERAPEUTICS INC (GMTX) Stock Price & Overview
NASDAQ:GMTX • US36870G1058
Current stock price
The current stock price of GMTX is 1.35 USD. Today GMTX is down by 0%. In the past month the price decreased by -21.51%. In the past year, price decreased by -53.61%.
GMTX Key Statistics
- Market Cap
- 58.454M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.81
- Dividend Yield
- N/A
GMTX Stock Performance
GMTX Stock Chart
GMTX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GMTX. When comparing the yearly performance of all stocks, GMTX is a bad performer in the overall market: 84.99% of all stocks are doing better.
GMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GMTX. GMTX has a great financial health rating, but its profitability evaluates not so good.
GMTX Earnings
GMTX Forecast & Estimates
6 analysts have analysed GMTX and the average price target is 1.53 USD. This implies a price increase of 13.33% is expected in the next year compared to the current price of 1.35.
GMTX Groups
Sector & Classification
GMTX Financial Highlights
Over the last trailing twelve months GMTX reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS increased by 29.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
GMTX Ownership
GMTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 354.636B | ||
| AMGN | AMGEN INC | 15.15 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.79 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.5 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GMTX
Company Profile
Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2020-08-12. The firm is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The firm's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH to construct that express GEM103 continuously at a therapeutic level. Its pipeline is designed to develop treatments for genetically subpopulations of patients suffering from dry AMD and linked diseases. The firm do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.
Company Info
IPO: 2020-08-12
GEMINI THERAPEUTICS INC
300 One Kendall Square, 3Rd Floor, Suite 4500
Cambridge MASSACHUSETTS 94111 US
CEO: Jason Meyenburg
Employees: 31
Phone: 16174014400.0
GEMINI THERAPEUTICS INC / GMTX FAQ
What does GEMINI THERAPEUTICS INC do?
Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2020-08-12. The firm is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The firm's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH to construct that express GEM103 continuously at a therapeutic level. Its pipeline is designed to develop treatments for genetically subpopulations of patients suffering from dry AMD and linked diseases. The firm do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.
What is the stock price of GEMINI THERAPEUTICS INC today?
The current stock price of GMTX is 1.35 USD.
Does GEMINI THERAPEUTICS INC pay dividends?
GMTX does not pay a dividend.
What is the ChartMill rating of GEMINI THERAPEUTICS INC stock?
GMTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Should I buy GMTX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GMTX.
How many employees does GEMINI THERAPEUTICS INC have?
GEMINI THERAPEUTICS INC (GMTX) currently has 31 employees.
What is the market capitalization of GMTX stock?
GEMINI THERAPEUTICS INC (GMTX) has a market capitalization of 58.45M USD. This makes GMTX a Micro Cap stock.